Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue guidance and ongoing competitive pressures in the vaccine market.

McLellan, who will be inducted in Washington, D.C. on May 8, is among the youngest new inductees in hall of fame history.

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

New York Amsterdam News | Word In Black (WIB) - With the triad of respiratory viruses present in our day-to-day, it ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...